Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02752646|
Recruitment Status : Completed
First Posted : April 27, 2016
Last Update Posted : March 7, 2017
|Condition or disease||Intervention/treatment||Phase|
|Cataract||Drug: nepafenac 0.3% Drug: ketorolac||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%|
|Study Start Date :||April 2016|
|Actual Primary Completion Date :||March 1, 2017|
|Actual Study Completion Date :||March 1, 2017|
Active Comparator: nepafenac 0.3%
Patients in this arm will receive nepafenac 0.3% eye drops once daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
Drug: nepafenac 0.3%
Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
Other Name: Ilevro
Active Comparator: ketorolac 0.5%
Patients in this arm will receive ketorolac 0.5% eye drops four times daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.
- Tolerability of nepafenac vs ketorolac [ Time Frame: 14-28 days ]Patients will fill out a survey describing eye drop tolerability at 14-28 days
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02752646
|United States, California|
|Harvard Eye Associates|
|Laguna Hills, California, United States, 92653|
|United States, Kentucky|
|Cincinnati Eye Institute|
|Edgewood, Kentucky, United States, 41017|
|Principal Investigator:||John A Hovanesian, MD||UCLA Jules Stein Eye Institute|